This disclosure generally relates to aerosol delivery systems and related methods, and, more particularly, to aerosol delivery units suitable for selectively delivering a dose of aerosolized matter for inhalation by a user.
It is well known to treat patients with medicaments contained in an aerosol, for example, in the treatment of respiratory disorders. It is also known to use for such treatment, medicaments which are contained in an aerosol and are administered to a patient by means of an inhalation device comprising a mouthpiece and a housing in which an aerosol canister is loaded. Such inhalation devices are generally referred to as metered dose inhalers (MDIs). The aerosol canisters used in such inhalation devices are designed to deliver a predetermined dose of medicament upon each actuation by means of an outlet valve member (e.g., metering slide valve) at one end which can be opened either by depressing the valve member while the canister is held stationary or by depressing the canister while the valve member is held stationary. In the use of such devices, the aerosol canister is placed in the housing with the outlet valve member of the canister communicating with the mouthpiece. When used for dispensing medicaments, for example, in bronchodilation therapy, the patient holds the housing in a more or less upright position and the mouthpiece of the inhalation device is placed in the mouth of the patient. The aerosol canister is manually actuated to dispense a dose of medicament from the canister which is then inhaled by the patient.
It may be understood that effective delivery of medicament to the patient using an inhalation device such as a conventional MDI is to an extent dependent on the patient's ability to manually actuate the device (e.g., discharging the aerosol) and to coordinate the actuation thereof with the taking of a sufficiently strong inward breath. For some patients, particularly young children, the elderly and the arthritic, manual actuation of the device can present difficulties. Other patients find it difficult to coordinate the taking of a reliable inward breath with actuation of the device. Thus, there is a risk of not receiving an appropriate dose of medicament. Conventional manually actuated MDIs also suffer from a variety of other deficiencies and drawbacks, including, for example, the ability to actuate the device while not in a generally upright position or without ensuring the medicament is sufficiently agitated within the container prior to delivery.
Embodiments described herein provide aerosol delivery systems and related methods particularly suitable for delivering a dose of aerosolized matter in an efficient and reliable manner for inhalation by a user. Embodiments include aerosol delivery systems featuring electronically controlled, motor-driven actuation of an aerosol canister which may be triggered by breath sensing techniques. Embodiments may be provided in multi-part form factors featuring a base housing including a motor-driven actuator and other system components, and a removable cartridge insertably receivable in the base housing to form a complete aerosol delivery unit for selectively delivering a dose of aerosolized matter to the user. Advantageously, the removable cartridge may be configured to enable manual actuation of the aerosol canister while removed from the main housing similar to a conventional MDI while providing enhanced functionality when received in the main housing.
Embodiments of the electronically controlled, motor-driven, breath actuated aerosol delivery systems described herein may provide enhanced user experience and may facilitate increased compliance by both simplifying the inhalation process and by providing targeted information to the user. To do this the aerosol delivery systems automate primary functions such as breath timing and canister actuation while also being instrumented to capture usage data which can be used to inform the user on correct inhalation technique. Information may be supplied to the user on board an aerosol delivery unit through a display screen, for example, through haptic and/or audible feedback and/or via an associated application running on a paired smart phone or other computing device with which the aerosol delivery unit may communicate wirelessly.
In the following description, certain specific details are set forth in order to provide a thorough understanding of various disclosed embodiments. However, one of ordinary skill in the relevant art will recognize that embodiments may be practiced without one or more of these specific details. In other instances, well-known structures and devices associated with MDIs or other inhaler devices or components may not be shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments.
Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is as “including, but not limited to.”
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
Embodiments described herein provide aerosol delivery systems and related methods particularly suitable for delivering a dose of aerosolized matter in an efficient and reliable manner for inhalation by a user. Embodiments include aerosol delivery systems featuring electronically controlled, motor-driven actuation of an aerosol canister which may be triggered by breath sensing techniques. Embodiments may be provided in multi-part form factors featuring a base housing including the motor-driven actuator and other system components, and a removable cartridge containing an aerosol canister which may be insertably received in the base housing to form a complete aerosol delivery unit for selectively delivering a dose of aerosolized matter (e.g., medicament) to a user. Advantageously, the removable cartridge may be configured to enable manual actuation of the aerosol canister when removed from the main housing similar to a conventional MDI while providing enhanced functionality when received in the main housing. Other advantages will be appreciated from a detailed review of the present disclosure.
Although the aerosol delivery systems described herein are shown and described in the context of electronically controlled, motor-driven, breath actuated metered dose inhaler systems for delivering medicament or other aerosolized matter to a user, it will be appreciated by those of ordinary skill in the relevant art that features and aspects of such systems may applied to other devices and for other purposes.
With reference to
With continued reference to
According to the example embodiment shown in
With reference to
With continued reference to
Advantageously, when the mouthpiece cover 234 is in the open position 236, the mouthpiece cover 234 may hinder or prevent a user from inadvertently covering unit intake apertures 312 (
With reference to
The base housing 212 is provided with, among other features, a control system 250, including a main printed circuit board (PCB) 252 and a sub PCB 253, and an actuator assembly 260 electronically coupled to the PCBs 252, 253 for providing controlled actuation of the aerosol canister 216. Further details of the actuator assembly 260 are shown in
With reference to
During actuation, the electric motor 262 is driven by the control system 250 in response to a trigger signal to move the canister 216 through the sequence illustrated in
With reference to
According to the illustrated embodiment, the worm screw 264c has an axis of rotation parallel to an axis of rotation of the electric motor 262 and the worm wheel 264d is meshed with the worm screw 264c to rotate perpendicular thereto. In some instances, the cam member 266 and the worm wheel 264d may be portions of the same unitary part such that a rotational position of the electric motor 262 controls the rotational position of the cam member 266 via the intermediary of the driven spur gear 264b and the worm gear set 264c, 264d. During actuation, and as previously described, the cam member 266 rides in the slot 267 of the yoke 268 and bears against the yoke 268 to urge the yoke 268 downward into contact with the canister 216 during a downward stroke to move the canister 216 into the depressed configuration D and to thereafter enable the yoke 268 to move back upward during a return stroke to enable the canister 216 to return to the expanded configuration E under the force of an internal bias member of the canister 216.
More particularly, as the motor 262 drives in a forward direction, the yoke 268 moves linearly downward and depresses the canister 216. Since the canister valve stem 217 is fixed in the stem support 302 (
In order to prevent the motor 262 from wasting power and overheating when it is stalled (e.g., due to the canister 216 reaching the end-stop during actuation or due to the motor 262 otherwise reaching its stall torque), the control system 250 may monitor feedback signals from the motor control electronics which exhibit distinct patterns when the motor 262 is running or stalled. Once stall is detected, forward drive power to the motor 262 is cut. The control system 250 may then wait for a dwell-time sufficient to ensure that the matter delivered by through the valve stem 217 has time to vaporize and enter the inhalation passageway 296. The motor 262 is then driven in the reverse direction until it stalls on a worm-wheel home position end stop. A canister valve spring causes the canister 216 to return to its normal position, allowing the metering valve to refill in readiness for a subsequent dose.
Advantageously, in some embodiments, the entire gear train 264a-264d, the cam member 266 and the yoke 268 may be injection molded plastic components and may be supported without separate bearings (e.g., roller bearings). In this manner, the weight of the actuator assembly 260 may be minimized and the complexity of the assembly reduced. Overall, the actuator assembly 260 shown in
With reference again to
In some instances, the actuator assembly 260 may be controlled to actuate the aerosol canister 216 in response to a pressure signal arising from inhalation of a user via a mouthpiece 215 of the removable cartridge 214. For this purpose, the control system 250 may further include a pressure sensor 280 (e.g., a microelectromechanical systems (MEMS) pressure sensor) communicatively coupled to the main PCB 252. In some instances, the pressure sensor 280 may be coupled directly to the main PCB 252 and may be positioned to interface with the removable cartridge 214 to sense a change in pressure within the removable cartridge 214 arising from inhalation by a user in order to trigger actuation of the aerosol canister 216. The pressure sensor 280 may further include temperature sensing functionality or otherwise operate in conjunction with a separate temperature sensor to provide pressure and temperature data for calculating the air flow rate through the unit 210 from which to trigger the actuation of the aerosol canister 216.
For instance, with reference to the enlarged cross-sectional view of
The pressure sensor 80 may be arranged to detect pressure within the inhalation passageway 96 near the one or more inhalation passageway intake apertures or orifices 94, with a change in the pressure being indicative of one or more characteristics of a flow of air moving through the one or more inhalation passageway intake apertures or orifices 94. A compliant seal 104 may be positioned around the pressure sensor 80 to engage the removable cartridge 14 and provide a sealed passageway 106 extending from the pressure sensor 80 toward the inhalation passageway 96 of the removable cartridge 14. In this manner, during inhalation, air may enter the inhalation passageway 96 only through the one or more inhalation passageway intake apertures or orifices 94 to subsequently pass through the inhalation passageway 96 wherein the aerosolized matter is mixed with the air stream and withdrawn from the mouthpiece aperture 92 by the user.
With continued reference to
Although the inhalation passageway intake apertures or orifices 94 of the illustrated embodiment include two relatively small apertures having a circular cross-sectional profile and being positioned immediately adjacent a respective sidewall of the cartridge body 90 that defines the inhalation passageway 96, it is appreciated that the number, size, shape and position of the inhalation passageway intake apertures or orifices 94 may vary. For example, one, three, four or more inhalation passageway intake orifices 94 may be provided and the orifice(s) may have an oblong or other regular or irregular cross-sectional shape. In addition, although the one or more inhalation passageway intake apertures or orifices 94 are shown as being provided in a separate orifice plate 110 coupled to an intake end of the cartridge body 90, it is appreciated that in some instances the one or more intake apertures or orifices 94 may be provided directly in the cartridge body 90. For example, in some embodiments, the orifice plate 110 may be an integral portion of the cartridge body 90, rather than a separate component. The housing body 22 of the base housing 12 which surrounds the removable cartridge 14 during motor-driven, breath actuated use of the aerosol delivery unit 10 may include one or more unit intake apertures 112 for enabling external air to infiltrate the housing body 22 before moving through the inhalation passageway intake apertures or orifices 94 provided in the inhalation passageway 96 of the removable cartridge 14, which, apart from the inhalation passageway intake apertures or orifices 94 and mouthpiece aperture 92, is otherwise sealed.
As another example, and with reference to the cross-sectional views of
With reference to
With continued reference to
Although the inhalation passageway apertures or orifices 294 of the illustrated embodiment include two relatively small apertures having a circular cross-sectional profile which are positioned on opposing sides of the stem support 302, it is appreciated that the number, size, shape and position of the cartridge intake apertures or orifices 294 may vary. For example, one, three, four or more intake orifices 294 may be provided and the orifice(s) may have an oblong or other regular or irregular cross-sectional shape.
As shown in
With reference back to
In some embodiments, the aerosol canister 16 and the power source 120 may be accommodated in adjacent compartments of the removable cartridge 14. In other embodiments, the aerosol canister 16 and the power source 120 may be provided in the same compartment. In some instances, the power source 120 may be shaped to conform around at least a portion of the canister 16 to provide additional space savings and to reduce the overall form factor of the aerosol delivery unit 10.
The removable cartridge 14 may comprise electrical contacts (not visible), such as on a rear end of the cartridge 14 for providing power from the power source 120 carried onboard the cartridge 14 to the actuator assembly (not visible) and other system components provided in the base housing 12 when the cartridge 14 is coupled to the base housing 12 for use. A supplemental PCB (not visible) may be provided in the removable cartridge 14 and may be in electrical communication with the power source 120 and the aforementioned electrical contacts.
Although the removable cartridge 14 of the example embodiment of the aerosol delivery unit 10 shown in
With reference to
With continued reference to
The control system may also include a wireless communication module (e.g., Bluetooth module), which may be integrated with the main PCB or other PCB component, for exchanging information with a remote device, such as, for example, a smart phone or other computing device. In this manner, various data, including dose information, may be communicated to the remote device for various purposes, as described in more detail elsewhere.
The base housing 12 may further include one or more external control devices 130 (e.g., buttons, switches, touch controls) for controlling one or more ancillary functions. For example, in some embodiments, a push-button control may be provided for triggering a priming function in which the canister 16 is actuated at least once by the actuator assembly prior to actuation of the canister 16 in response to breath actuation by the user. In other embodiments, the base housing 12 may be completely devoid of any external controls and the aerosol delivery unit 10 may function entirely via spatial manipulation of the aerosol delivery unit 10 and user-interaction with the mouthpiece 15.
With reference to the embodiment of the aerosol delivery unit shown in
In some embodiments, the aerosol canister 216 and the power source 320 may be accommodated in adjacent compartments of the canister chassis 293. In other embodiments, the aerosol canister 216 and the power source 320 may be provided in the same compartment. In some instances, the power source 320 may be shaped to conform around at least a portion of the canister 216 to provide additional space savings and to reduce the overall form factor of the aerosol delivery unit 210.
The removable cartridge 214 may comprise electrical contacts 219 (not visible), such as on a rear facing end of the cartridge 214 for providing power from the power source 320 carried onboard the cartridge 214 to the actuator assembly 260 and other system components provided in the base housing 212 when the cartridge 214 is coupled to the base housing 212 for use. A supplemental PCB 255 (
Although the removable cartridge 214 of the example embodiment of the aerosol delivery unit 210 shown in
A dose counter arrangement, including a depressible carriage and a counter switch, may be provided within the removable cartridge 214 so as to count and track the number of doses administered and/or remaining in the removable cartridge 214. The dose counter arrangement may be electrically coupled to the supplemental PCB 255 and a storage device (e.g., non-volatile memory) integrated in the supplemental PCB 255 for storing dose information and optionally communicating the dose information to other portions of the control system 250, including, for example, the PCBs 252, 253 provided in the base housing 212. One or more additional switches may also be provided for ensuring that a dose count is valid only when the system is properly assembled. For example, the canister chassis 293 carrying the aerosol canister 216 and the power source 320 may include a switch or operate in connection with a switch that is activated when the canister chassis 293 is properly seated within the mouthpiece subassembly 295 of the removable cartridge 214 with the valve stem 217 of the canister properly engaging the stem support 302. For example, as shown in
With reference to
The control system 250 may also include a wireless communication module (e.g., Bluetooth module), which may be integrated with the main PCB 252 or the sub PCB253, for exchanging information with a remote device, such as, for example, a smart phone or other computing device. In this manner, various data, including dose information, may be communicated to the remote device for various purposes, as described in more detail elsewhere.
Although embodiments of the aerosol delivery units 10, 210, 410 are depicted herein as front cartridge loading and bottom cartridge loading devices, it is appreciated that a removable cartridge containing, among other things, a canister of matter to be discharged and an associated discharge passageway, may be configured to mate with a base housing containing, among other things, a actuator for firing the canister, from any direction, including, for example, front, bottom, rear and side directions.
Additional features and functionality will now be described with reference to
In the depicted embodiment, the resident control portion 1002 includes one or more microprocessors 1010 that includes or is communicatively coupled to one or more transmitters (such as a low-energy Bluetooth radio transmitter). In other embodiments, the microprocessor may include or be communicatively coupled to additional transmitter types, or may omit such transmitter. As depicted, the one or more microprocessors 1010 are communicatively coupled to a power management module 1012; one or more memories 1014, such as may store various information and/or processor-executable instructions related to operations of the control system 1000; one or more antennas 1016; a vibration motor 1018, such as may provide vibratory or other tactile feedback for users of the associated aerosol delivery unit; an audio buzzer 1020, such as may provide audio feedback for users of the associated aerosol delivery unit; a user-selectable priming button 1022, such as may allow a user of the associated aerosol delivery unit to manually trigger a priming function; a display 1024, such as to provide visual information or feedback to a user of the aerosol delivery unit; one or more accelerometers 1026, such as may provide data signals to the microprocessor 1010 indicative of an orientation or motion of the aerosol delivery unit; an actuator 1028 for selectively actuating the canister 1050, and a pressure sensor 1030 for sensing air flow arising from inhalation by a user from which to trigger actuation of the canister 1050.
The mouthpiece control portion 1004 includes a mouthpiece cover sensor 1032 communicatively coupled to the one or more microprocessors 1010, and mouthpiece cover 1034, which may be functionally analogous to mouthpiece cover 34 of the example aerosol delivery unit 10 shown in
In the depicted embodiment of
In accordance with the control system 1000 of
Various example graphical user interface (“GUI”) screens are now presented with respect to particular embodiments shown for illustrative purposes, although it will be appreciated that other embodiments may include more and/or less information, and that various types of illustrated information may be replaced with other information.
In the illustrated examples of
In particular,
Each of the dosage information entries 1122 indicates a date and time at which the respective dose was delivered via the aerosol delivery unit, as well as whether such dose consisted of a single “puff” or a second such inhalation. In addition, in various embodiments the dosage information entries may provide certain other visual indicia of information associated with the particular dosage entry. For example, dosage information entry 1122a includes a flag indicator to denote that only a single inhalation was utilized for that respective dose as well as a user-selectable “+” control to allow the user to view additional information related to the respective dose. Similarly, dosage information entry 1122b provides a user-selectable message control, allowing the user to view textual information associated with the entry.
In certain embodiments, the aerosol delivery system interface and/or GUI 1100 may allow the user to select and configure one or more reminders, alerts, or other notifications based on data provided by the communicatively coupled aerosol delivery unit and its associated control system. For example, the user may configure the system interface to provide a reminder within a predetermined time of a scheduled dose; to provide an alert when the user has failed to inhale a dose within a predetermined duration from the last administered dose; to provide one or more notifications regarding a quantity of doses remaining in the currently interfaced consumable canister, such as if a threshold quantity has been exceeded; etc. In at least some embodiments, the user may configure the aerosol delivery system interface to provide such notifications or alerts to other users, such as providing a “shared” notification to one or more family members or medical professionals associated with the user.
In the illustrated example of
It will be appreciated that the GUIs, display screens and other information presented with respect to
Although aspects of the embodiments have been described above in connection with a consumable cartridge control portion, it will be appreciated that in some embodiments, the cartridge control portion, or parts thereof, may be non-consumable or durable. In some embodiments, for example, only the canister itself may be consumable while the removable cartridge that accommodates the canister is reusable throughout the life of the aerosol delivery unit.
In accordance with the systems described above, an example method implemented by a processor-based electronic client device may be summarized as including: receiving, by the processor-based electronic client device while communicatively coupled to an aerosol delivery unit and via one or more electronic communications sent over a wireless interface of the electronic client device, aerosol delivery data from the aerosol delivery device, the aerosol delivery data being related to one or more user interactions with the aerosol delivery unit; generating, by the processor-based electronic client device and based at least in part on the received aerosol delivery information, aerosol delivery tracking information regarding the one or more user interactions; and providing, via the processor-based electronic client device, one or more indications regarding at least one of the aerosol delivery tracking information and the aerosol delivery data.
In some instances, providing one or more indications to the user may include displaying, via a user interface of the electronic client device: one or more error messages related to the motion or the orientation of a canister interfaced with the aerosol delivery unit; an indication of estimated battery power remaining to the aerosol delivery unit; one or more reminder notifications regarding a scheduled dose of matter; and/or instructional information regarding use of the aerosol delivery unit. In addition to or in lieu of such displaying on the electronic client device, one or more error messages, indication of battery power remaining and/or instructional use information may likewise be displayed on a screen or other display device of the aerosol delivery unit itself.
In some instances, receiving aerosol delivery data from the aerosol delivery unit may include receiving at least one of a group that includes: data indicative of a motion or orientation of a canister interfaced with the aerosol delivery unit; data identifying matter contained in the canister; data indicative of a quantity of matter remaining in the canister; data indicative of a quantity of matter expended from the canister; data indicative of a number of doses of matter expended from the canister; and data indicative of a number of doses of matter remaining in the canister.
In some instances, receiving aerosol delivery data from the aerosol delivery unit may include receiving data indicative of a quantity of doses of matter expended from the canister, and generating the aerosol delivery tracking information may includes generating a quantity of doses of matter remaining in the canister. In some instances, generating the aerosol delivery tracking information may include generating dosage history information for a user associated with the processor-based electronic client device. Generating the dosage history information may include generating dosage history information based at least in part on one or more canisters previously interfaced with the aerosol delivery unit.
In some instances, the processor-based electronic client device may be associated with a first user, and providing one or more indications may include providing one or more notifications to one or more distinct other users regarding the first user's interactions with the aerosol delivery unit.
In accordance with aspects of the embodiments of the aerosol delivery units disclosed herein, an aerosol delivery system for selectively delivering a dose of aerosolized matter may be summarized as including: an aerosol delivery unit configured to receive a canister containing the matter to be aerosolized; one or more accelerometers; one or more processors; and at least one memory, the memory including instructions that, upon execution by at least one of the one or more processors, cause the aerosol delivery system to provide, via a user interface of a client device associated with a user of the aerosol delivery unit, one or more indications of information related to a canister interfaced with the aerosol delivery unit. The information may include, for example, at least one of a group that includes: a motion or orientation of the canister; a quantity of matter remaining in the canister, a quantity of matter expended from the canister, a number of doses of matter expended from the canister, and an estimated number of doses of matter remaining in the canister. The indicated information may further include one or more identifiers associated with matter contained in the canister.
In some instances, the instructions may further cause the associated client device or a display of the aerosol delivery unit to display one or more error messages related to the motion or the orientation of the canister; an indication of estimated battery power remaining to the aerosol delivery unit; one or more reminder notifications regarding a scheduled dose of matter; and/or instructional information regarding use of the aerosol delivery unit. Other features and functionality will be readily apparent by one of ordinary skill in the relevant art upon reviewing the present disclosure.
Moreover, aspects and features of the various embodiments described above may be combined to provide further embodiments. These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled.
This application claims priority to U.S. Provisional Application No. 62/194,701, filed Jul. 20, 2015, and U.S. Provisional Application No. 62/212,379, filed Aug. 31, 2015, which applications are incorporated herein by reference in their entireties.
This application is a continuation of U.S. patent application Ser. No. 15/743,239, filed Jan. 9, 2018, which is a 371 of PCT/US2016/043004 filed Jul. 19, 2016, which claims the benefit of U.S. provisional application Nos. 62/194,701, filed Jul. 20, 2015, and 62/212,379, filed Aug. 31, 2015, the entire contents of which are hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
5224472 | Pesenti et al. | Jul 1993 | A |
5284133 | Burns et al. | Feb 1994 | A |
5347998 | Hodson et al. | Sep 1994 | A |
5363842 | Mishelevich et al. | Nov 1994 | A |
5392768 | Johansson et al. | Feb 1995 | A |
5394866 | Ritson et al. | Mar 1995 | A |
5404871 | Goodman et al. | Apr 1995 | A |
5419315 | Rubsamen | May 1995 | A |
5450336 | Rubsamen et al. | Sep 1995 | A |
5469750 | Lloyd et al. | Nov 1995 | A |
5487378 | Robertson et al. | Jan 1996 | A |
5497764 | Ritson et al. | Mar 1996 | A |
5505195 | Wolf et al. | Apr 1996 | A |
5520166 | Ritson et al. | May 1996 | A |
5522378 | Ritson et al. | Jun 1996 | A |
5542410 | Goodman et al. | Aug 1996 | A |
5608647 | Rubsamen et al. | Mar 1997 | A |
5622162 | Johansson et al. | Apr 1997 | A |
5655516 | Goodman et al. | Aug 1997 | A |
5655523 | Hodson et al. | Aug 1997 | A |
5676129 | Rocci, Jr. et al. | Oct 1997 | A |
5692492 | Bruna et al. | Dec 1997 | A |
5694919 | Rubsamen et al. | Dec 1997 | A |
5694920 | Abrams et al. | Dec 1997 | A |
5724986 | Jones, Jr. et al. | Mar 1998 | A |
5743252 | Rubsamen et al. | Apr 1998 | A |
5755218 | Johansson | May 1998 | A |
5809997 | Wolf | Sep 1998 | A |
5813397 | Goodman et al. | Sep 1998 | A |
5826570 | Goodman et al. | Oct 1998 | A |
5855564 | Ruskewicz | Jan 1999 | A |
5894841 | Voges | Apr 1999 | A |
5921237 | Eisele et al. | Jul 1999 | A |
5954047 | Armer | Sep 1999 | A |
5971951 | Ruskewicz | Oct 1999 | A |
6006747 | Eisele et al. | Dec 1999 | A |
6012454 | Hodson et al. | Jan 2000 | A |
6026808 | Armer et al. | Feb 2000 | A |
6026809 | Abrams et al. | Feb 2000 | A |
6055980 | Mecikalski et al. | May 2000 | A |
6095141 | Armer et al. | Aug 2000 | A |
6116238 | Jackson et al. | Sep 2000 | A |
6119684 | Nöhl et al. | Sep 2000 | A |
6123068 | Lloyd et al. | Sep 2000 | A |
6138669 | Rocci, Jr. et al. | Oct 2000 | A |
6142146 | Abrams et al. | Nov 2000 | A |
6148815 | Wolf | Nov 2000 | A |
6152130 | Abrams et al. | Nov 2000 | A |
6196218 | Voges | Mar 2001 | B1 |
6234167 | Cox et al. | May 2001 | B1 |
6260549 | Sosiak | Jul 2001 | B1 |
6273085 | Eisele et al. | Aug 2001 | B1 |
6318361 | Sosiak | Nov 2001 | B1 |
6325062 | Sosiak | Dec 2001 | B1 |
6328034 | Eisele et al. | Dec 2001 | B1 |
6341603 | Howlett | Jan 2002 | B1 |
6354290 | Howlett | Mar 2002 | B1 |
6358058 | Strupat et al. | Mar 2002 | B1 |
6360739 | Rand et al. | Mar 2002 | B1 |
6425392 | Sosiak | Jul 2002 | B1 |
6431168 | Rand et al. | Aug 2002 | B1 |
6443146 | Voges | Sep 2002 | B1 |
6474331 | Rand et al. | Nov 2002 | B1 |
6516796 | Cox et al. | Feb 2003 | B1 |
6557552 | Cox et al. | May 2003 | B1 |
6601582 | Rand et al. | Aug 2003 | B2 |
6651651 | Bonney et al. | Nov 2003 | B1 |
D483860 | Knoch | Dec 2003 | S |
6656114 | Poulsen et al. | Dec 2003 | B1 |
6684879 | Coffee et al. | Feb 2004 | B1 |
6698421 | Attolini | Mar 2004 | B2 |
6745761 | Christrup et al. | Jun 2004 | B2 |
6805116 | Hodson et al. | Oct 2004 | B2 |
6823863 | Huxham et al. | Nov 2004 | B2 |
6830046 | Blakley et al. | Dec 2004 | B2 |
6854461 | Nichols et al. | Feb 2005 | B2 |
6871535 | Blakley et al. | Mar 2005 | B2 |
6889690 | Crowder et al. | May 2005 | B2 |
6904907 | Speldrich et al. | Jun 2005 | B2 |
6933850 | Garcia et al. | Aug 2005 | B2 |
6958691 | Anderson et al. | Oct 2005 | B1 |
6978780 | Marnfeldt et al. | Dec 2005 | B1 |
6981499 | Anderson et al. | Jan 2006 | B2 |
6983652 | Blakley et al. | Jan 2006 | B2 |
6985798 | Crowder et al. | Jan 2006 | B2 |
7021560 | Gray et al. | Apr 2006 | B2 |
7047964 | Bacon | May 2006 | B2 |
7066029 | Beavis et al. | Jun 2006 | B2 |
7107986 | Rand et al. | Sep 2006 | B2 |
7117867 | Cox et al. | Oct 2006 | B2 |
7118010 | Crowder et al. | Oct 2006 | B2 |
7146977 | Beavis et al. | Dec 2006 | B2 |
7191777 | Brand et al. | Mar 2007 | B2 |
7219664 | Ruckdeschel et al. | May 2007 | B2 |
7225805 | Bacon | Jun 2007 | B2 |
7252085 | Kunschir | Aug 2007 | B2 |
7282029 | Poulsen et al. | Oct 2007 | B1 |
7305984 | Altobelli et al. | Dec 2007 | B2 |
7322355 | Jones et al. | Jan 2008 | B2 |
7347200 | Jones et al. | Mar 2008 | B2 |
7347202 | Aslin et al. | Mar 2008 | B2 |
7367333 | Hodson et al. | May 2008 | B2 |
7380550 | Sexton et al. | Jun 2008 | B2 |
7383740 | Krasilchikov et al. | Jun 2008 | B2 |
7383837 | Robertson et al. | Jun 2008 | B2 |
7387121 | Harvey | Jun 2008 | B2 |
7418961 | Jones et al. | Sep 2008 | B2 |
7428446 | Crowder et al. | Sep 2008 | B2 |
7458373 | Nichols et al. | Dec 2008 | B2 |
7461650 | Rand | Dec 2008 | B1 |
7467629 | Rand | Dec 2008 | B2 |
7472701 | Pfichner et al. | Jan 2009 | B2 |
7481213 | Childers | Jan 2009 | B2 |
7520278 | Crowder et al. | Apr 2009 | B2 |
7562657 | Blanch et al. | Jul 2009 | B2 |
7597099 | Jones et al. | Oct 2009 | B2 |
7607435 | Lipp | Oct 2009 | B2 |
7677411 | Crowder et al. | Mar 2010 | B2 |
7743765 | Hodson et al. | Jun 2010 | B2 |
7784459 | Abrams | Aug 2010 | B2 |
7806116 | Altobelli et al. | Oct 2010 | B2 |
7814902 | Abrams | Oct 2010 | B2 |
7819116 | Brand et al. | Oct 2010 | B2 |
7832394 | Schechter et al. | Nov 2010 | B2 |
7837648 | Blair et al. | Nov 2010 | B2 |
7886934 | Lu et al. | Feb 2011 | B2 |
7896002 | Watanabe | Mar 2011 | B2 |
8044778 | Monroe | Oct 2011 | B2 |
8056556 | Childers et al. | Nov 2011 | B2 |
8082917 | Ooida | Dec 2011 | B2 |
8082918 | Jansen et al. | Dec 2011 | B2 |
8082919 | Brunnberg et al. | Dec 2011 | B2 |
8091545 | Schechter et al. | Jan 2012 | B2 |
8109266 | Addington et al. | Feb 2012 | B2 |
8146592 | Voege et al. | Apr 2012 | B2 |
8210172 | Crowder et al. | Jul 2012 | B2 |
8212658 | Monroe | Jul 2012 | B2 |
8240301 | Spaargaren et al. | Aug 2012 | B2 |
8240303 | Hamano | Aug 2012 | B2 |
8245704 | Rand et al. | Aug 2012 | B2 |
8291902 | Abrams | Oct 2012 | B2 |
8314591 | Terry et al. | Nov 2012 | B2 |
8333190 | Addington et al. | Dec 2012 | B2 |
8342172 | Levy et al. | Jan 2013 | B2 |
8357114 | Poutiatine et al. | Jan 2013 | B2 |
8408208 | Bacon | Apr 2013 | B2 |
8424517 | Sutherland et al. | Apr 2013 | B2 |
8464707 | Jongejan et al. | Jun 2013 | B2 |
8474452 | Gumaste et al. | Jul 2013 | B2 |
8511299 | Altobelli et al. | Aug 2013 | B2 |
8539945 | Solomon et al. | Sep 2013 | B2 |
8544466 | Blanch et al. | Oct 2013 | B2 |
8544645 | Edwards et al. | Oct 2013 | B2 |
8567394 | Herder et al. | Oct 2013 | B2 |
8573203 | Addington et al. | Nov 2013 | B2 |
8584668 | Hodson et al. | Nov 2013 | B2 |
8640971 | Feriani et al. | Feb 2014 | B2 |
8671934 | Addington et al. | Mar 2014 | B2 |
8712794 | Hyde et al. | Apr 2014 | B2 |
8739790 | Bruna | Jun 2014 | B2 |
8746238 | Kohnle | Jun 2014 | B2 |
8763606 | Mosier et al. | Jul 2014 | B2 |
8800559 | Bowman et al. | Aug 2014 | B2 |
8800819 | Carriço et al. | Aug 2014 | B2 |
8807131 | Tunnell et al. | Aug 2014 | B1 |
8910625 | Mullinger et al. | Dec 2014 | B2 |
8978966 | Walsh et al. | Mar 2015 | B2 |
8985101 | Mosier | Mar 2015 | B2 |
8991390 | Akouka et al. | Mar 2015 | B2 |
9004062 | Lang et al. | Apr 2015 | B2 |
9035765 | Engelhard et al. | May 2015 | B2 |
9060715 | Schipper et al. | Jun 2015 | B2 |
9072464 | Haartsen et al. | Jul 2015 | B2 |
9072846 | Helmlinger | Jul 2015 | B2 |
9095175 | Terry et al. | Aug 2015 | B2 |
9108010 | Walsh et al. | Aug 2015 | B2 |
9152829 | Day et al. | Oct 2015 | B2 |
9162031 | Gumaste et al. | Oct 2015 | B2 |
9174013 | Walsh et al. | Nov 2015 | B2 |
9216260 | Walsh et al. | Dec 2015 | B2 |
9227029 | Addington et al. | Jan 2016 | B2 |
9242056 | Andersen et al. | Jan 2016 | B2 |
11040156 | Riebe et al. | Jun 2021 | B2 |
20010032644 | Hodson et al. | Oct 2001 | A1 |
20020011247 | Ivri et al. | Jan 2002 | A1 |
20020026938 | Hodson et al. | Mar 2002 | A1 |
20020040713 | Eisele et al. | Apr 2002 | A1 |
20020090601 | Strupat et al. | Jul 2002 | A1 |
20020123669 | Wickstrom | Sep 2002 | A1 |
20020189612 | Rand | Dec 2002 | A1 |
20020189615 | Henry et al. | Dec 2002 | A1 |
20030065536 | Hansen et al. | Apr 2003 | A1 |
20030079744 | Bonney et al. | May 2003 | A1 |
20030168057 | Snyder et al. | Sep 2003 | A1 |
20040025871 | Davies | Feb 2004 | A1 |
20040050385 | Bonney et al. | Mar 2004 | A1 |
20040065326 | MacMichael et al. | Apr 2004 | A1 |
20040079360 | Coffee et al. | Apr 2004 | A1 |
20040089299 | Bonney et al. | May 2004 | A1 |
20040094152 | Harvey et al. | May 2004 | A1 |
20040231667 | Horton et al. | Nov 2004 | A1 |
20040255936 | Urbanus | Dec 2004 | A1 |
20050022806 | Beaumont et al. | Feb 2005 | A1 |
20050028815 | Deaton et al. | Feb 2005 | A1 |
20050119604 | Bonney et al. | Jun 2005 | A1 |
20050133024 | Coifman | Jun 2005 | A1 |
20050161467 | Jones | Jul 2005 | A1 |
20050172958 | Singer et al. | Aug 2005 | A1 |
20050197621 | Poulsen et al. | Sep 2005 | A1 |
20050251289 | Bonney et al. | Nov 2005 | A1 |
20050274378 | Bonney et al. | Dec 2005 | A1 |
20060130829 | Sexton et al. | Jun 2006 | A1 |
20060213505 | Hodson et al. | Sep 2006 | A1 |
20060237009 | Jones et al. | Oct 2006 | A1 |
20060254581 | Genova et al. | Nov 2006 | A1 |
20060278225 | MacMichael et al. | Dec 2006 | A1 |
20060289005 | Jones et al. | Dec 2006 | A1 |
20070017506 | Bell et al. | Jan 2007 | A1 |
20070056585 | Davies et al. | Mar 2007 | A1 |
20070074722 | Giroux et al. | Apr 2007 | A1 |
20070125372 | Chen | Jun 2007 | A1 |
20070135691 | Zingelewicz et al. | Jun 2007 | A1 |
20070186923 | Poutiatine et al. | Aug 2007 | A1 |
20070227534 | Nobutani et al. | Oct 2007 | A1 |
20070295329 | Lieberman et al. | Dec 2007 | A1 |
20080017189 | Ruckdeschel et al. | Jan 2008 | A1 |
20080030309 | Darrouzet | Feb 2008 | A1 |
20080173301 | Deaton et al. | Jul 2008 | A1 |
20080177154 | Hansen et al. | Jul 2008 | A1 |
20080177155 | Hansen et al. | Jul 2008 | A1 |
20080178872 | Genova et al. | Jul 2008 | A1 |
20080223362 | Hamano | Sep 2008 | A1 |
20080228099 | Abrams et al. | Sep 2008 | A1 |
20090005735 | Wikner et al. | Jan 2009 | A1 |
20090114219 | Ferris et al. | May 2009 | A1 |
20090151716 | Abrams | Jun 2009 | A1 |
20090188490 | Han | Jul 2009 | A1 |
20090194104 | Van Sickle | Aug 2009 | A1 |
20090229607 | Brunnberg et al. | Sep 2009 | A1 |
20090308387 | Andersen et al. | Dec 2009 | A1 |
20100083964 | Brown et al. | Apr 2010 | A1 |
20100089394 | Sakurada et al. | Apr 2010 | A1 |
20100094099 | Levy | Apr 2010 | A1 |
20100180890 | Nobutani | Jul 2010 | A1 |
20100192948 | Sutherland et al. | Aug 2010 | A1 |
20100219263 | Feriani et al. | Sep 2010 | A1 |
20100250280 | Sutherland | Sep 2010 | A1 |
20100250697 | Hansen et al. | Sep 2010 | A1 |
20100263665 | Brown et al. | Oct 2010 | A1 |
20100326436 | Kaneko | Dec 2010 | A1 |
20110162642 | Akouka et al. | Jul 2011 | A1 |
20110225008 | Elkouh et al. | Sep 2011 | A1 |
20110253139 | Guthrie et al. | Oct 2011 | A1 |
20120003928 | Geboers et al. | Jan 2012 | A1 |
20120012106 | Bari | Jan 2012 | A1 |
20120048269 | Pardonge et al. | Mar 2012 | A1 |
20120048270 | Pardonge | Mar 2012 | A1 |
20120055472 | Brunnberg et al. | Mar 2012 | A1 |
20120080029 | Koerner et al. | Apr 2012 | A1 |
20120090605 | McDaid et al. | Apr 2012 | A1 |
20120190999 | Addington et al. | Jul 2012 | A1 |
20120227737 | Mastrototaro et al. | Sep 2012 | A1 |
20120240923 | Denyer et al. | Sep 2012 | A1 |
20120255548 | Denny et al. | Oct 2012 | A1 |
20120285447 | Schipper et al. | Nov 2012 | A1 |
20120293321 | Monroe | Nov 2012 | A1 |
20130008436 | Von Hollen et al. | Jan 2013 | A1 |
20130046477 | Hyde et al. | Feb 2013 | A1 |
20130053719 | Wekell | Feb 2013 | A1 |
20130087142 | Kane et al. | Apr 2013 | A1 |
20130092158 | Levy et al. | Apr 2013 | A1 |
20130133643 | Hodson et al. | May 2013 | A1 |
20130172690 | Arne et al. | Jul 2013 | A1 |
20130192594 | Addington et al. | Aug 2013 | A1 |
20130239957 | Pinfold | Sep 2013 | A1 |
20130269685 | Wachtel et al. | Oct 2013 | A1 |
20130269688 | Attolini | Oct 2013 | A1 |
20130269694 | Patton et al. | Oct 2013 | A1 |
20140000598 | Sutherland et al. | Jan 2014 | A1 |
20140000602 | Herder et al. | Jan 2014 | A1 |
20140007016 | Li | Jan 2014 | A1 |
20140007867 | Bruin et al. | Jan 2014 | A1 |
20140032243 | Solomon et al. | Jan 2014 | A1 |
20140053833 | Cline et al. | Feb 2014 | A1 |
20140060531 | Brambilla et al. | Mar 2014 | A1 |
20140096711 | Walsh et al. | Apr 2014 | A1 |
20140096769 | Walsh et al. | Apr 2014 | A1 |
20140148722 | Addington et al. | May 2014 | A1 |
20140158126 | Parry-Billings et al. | Jun 2014 | A1 |
20140174435 | Addington et al. | Jun 2014 | A1 |
20140182584 | Sutherland et al. | Jul 2014 | A1 |
20140202457 | Addington et al. | Jul 2014 | A1 |
20140202458 | Addington et al. | Jul 2014 | A1 |
20140216444 | Shtram et al. | Aug 2014 | A1 |
20140243749 | Edwards et al. | Aug 2014 | A1 |
20140246034 | Terry et al. | Sep 2014 | A1 |
20140246035 | Minskoff et al. | Sep 2014 | A1 |
20140251330 | Collins et al. | Sep 2014 | A1 |
20140261400 | Addington et al. | Sep 2014 | A1 |
20140305429 | Lewis | Oct 2014 | A1 |
20140352690 | Kolb et al. | Dec 2014 | A1 |
20140373838 | Herder et al. | Dec 2014 | A1 |
20150059739 | Aslam | Mar 2015 | A1 |
20150096555 | Wang et al. | Apr 2015 | A1 |
20150100276 | Huang et al. | Apr 2015 | A1 |
20150100335 | Englehard et al. | Apr 2015 | A1 |
20150101604 | Crosbie | Apr 2015 | A1 |
20150112707 | Manice et al. | Apr 2015 | A1 |
20150120320 | Fateh | Apr 2015 | A1 |
20150134358 | Fisher | May 2015 | A1 |
20150150484 | Wekell | Jun 2015 | A1 |
20150165137 | Mullinger et al. | Jun 2015 | A1 |
20150174348 | Tunnell et al. | Jun 2015 | A1 |
20150174349 | Tunnell et al. | Jun 2015 | A1 |
20150231342 | Walsh et al. | Aug 2015 | A1 |
20150235548 | Engelhard et al. | Aug 2015 | A1 |
20150238714 | Walsh et al. | Aug 2015 | A1 |
20150238715 | Walsh et al. | Aug 2015 | A1 |
20150246190 | Walsh et al. | Sep 2015 | A1 |
20150246191 | Walsh et al. | Sep 2015 | A1 |
20150246192 | Walsh et al. | Sep 2015 | A1 |
20150246193 | Walsh et al. | Sep 2015 | A1 |
20150249478 | Greiner | Sep 2015 | A1 |
20150273164 | Schipper et al. | Oct 2015 | A1 |
20150273165 | Hadash | Oct 2015 | A1 |
20150294551 | Edwards et al. | Oct 2015 | A1 |
20150297843 | Lu et al. | Oct 2015 | A1 |
20150335834 | Anandhakrishnan | Nov 2015 | A1 |
20150352281 | Pfrang | Dec 2015 | A1 |
20160001018 | Fink et al. | Jan 2016 | A1 |
20160001021 | Gumaste et al. | Jan 2016 | A1 |
20160019498 | Bhalodia et al. | Jan 2016 | A1 |
20170325734 | Sutherland et al. | Nov 2017 | A1 |
Number | Date | Country |
---|---|---|
1303309 | Jul 2001 | CN |
1 051 984 | Nov 2000 | EP |
1 358 902 | Nov 2003 | EP |
1 144 028 | Jun 2004 | EP |
1 726 322 | Nov 2006 | EP |
1 224 600 | Jun 2007 | EP |
2 514 463 | Oct 2012 | EP |
2 456 493 | Jun 2013 | EP |
2 638 925 | Sep 2013 | EP |
2 514 464 | Jul 2015 | EP |
10-2008-0030563 | Apr 2008 | KR |
9207600 | May 1992 | WO |
9215353 | Sep 1992 | WO |
9312823 | Jul 1993 | WO |
9416756 | Aug 1994 | WO |
9507724 | Mar 1995 | WO |
9841265 | Sep 1998 | WO |
9908737 | Feb 1999 | WO |
9949920 | Oct 1999 | WO |
0035524 | Jun 2000 | WO |
0126021 | Apr 2001 | WO |
02100468 | Dec 2002 | WO |
03043684 | May 2003 | WO |
03059413 | Jul 2003 | WO |
03063754 | Aug 2003 | WO |
03095010 | Nov 2003 | WO |
2004011068 | Feb 2004 | WO |
2005025654 | Mar 2005 | WO |
2006012205 | Feb 2006 | WO |
2006048417 | May 2006 | WO |
2006124517 | Nov 2006 | WO |
2007137991 | Dec 2007 | WO |
2008079350 | Jul 2008 | WO |
2009022139 | Feb 2009 | WO |
2010002421 | Jan 2010 | WO |
2010107912 | Sep 2010 | WO |
2012022771 | Feb 2012 | WO |
2012100164 | Jul 2012 | WO |
2013098334 | Jul 2013 | WO |
2014159016 | Oct 2014 | WO |
Entry |
---|
US 7,284,551 B2, 10/2007, Jones et al. (withdrawn) |
Murphy et al., “Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI,” Respiratory Medicine 109(2):1-10, 2015. |
Number | Date | Country | |
---|---|---|---|
20210369987 A1 | Dec 2021 | US |
Number | Date | Country | |
---|---|---|---|
62212379 | Aug 2015 | US | |
62194701 | Jul 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15743239 | US | |
Child | 17323824 | US |